Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages

Journal of Pediatrics

Volumn 134, Issue 5, 1999, Pages 597-606

  Sleasman, John W ^a,b,c,d,e,f   Nelson, Robert P ^a,b,c,d,e   Goodenow, Maureen M ^a,b,c,d,e   Wilfret, David ^a,b,c,d,e   Hutson, Alan ^a,b,c,d,e   Baseler, Michael ^a,b,c,d,e   Zuckerman, Judy ^a,b,c,d,e   Pizzo, Philip A ^a,b,c,d,e   Mueller, Brigitta U ^a,b,c,d,e  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c University of Florida ^*  (United States)

^d SAIC FREDERICK INC   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Box 100296 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; RITONAVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MIXTURE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFANT; LYMPHOCYTE COUNT; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0033497379     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70247-7     Document Type: Article

References (47)

1. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
2. 2. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Eingl J Med 1997;333:1534-9.
3. 3. Kelleher AD, Carr A, Zunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1995;173:321-9.
4. 4. Mueller BU, Nelson RP Jr, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM, et al. A phase I/II study of the protase inhibitor ritonavir in children with HIV infection. Pediatrics 1998;101:335-43.
5. 5. Dimitrov DS, Willey RL, Sato H, Chang L-J, Blumenthal R, Martin MA. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 1993;7:2182-90.
6. 6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;383:123-6.
7. 7. Sprent J, Tough D. CD4+ T cell turnover. Nature 1996;375:193.
8. 8. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV and SIV-infected lymph nodes. Nature Med 1995;1: 129-34.
9. 9. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
10. 10. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-4.
11. 11. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997;387:188-91.
12. 12. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
13. 13. George AJ, Ritter MA. Thymic involution with ageing: Obsolescence or good housekeeping? Immunol Today 1996;17:267-72.
14. 14. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J 1995;9:866-73.
15. 15. Plaeger-Marshall S, Isacescu V, O'Rourke S, Bertolli J, Bryson YJ, Stiehm ER. T cell activation in pediatric AIDS pathogenesis: three-color immunophenotyping. Clin Immunol Immunopathol 1994;71:19-26.
16. 16. Plaeger-Marshall S, Hultin P, Bertolli J, O'Rourke S, Kobayaski R, Kobayashi AL, et al. Activation and differentiation antigens on T cells of healthy, at-risk, and HIV-infected children. J Acquir Immune Defic Syndr Hum Retrovirol 1993;6:984-93.
17. + helper/inducer T lymphocytes defined by anti-CD45R antibodies derive sequentially from a differentiation pathway that is regulated by activation-dependent post-thymic differentiation. J Immunol 1988;141:1464-70.
18. 18. Clement LT. Isoforms of the CD45 common leukocyte antigen family: markets for human T-cell differentiation. J Clin Immunol 1992;12:1-10.
19. 19. De Paoli P, Battistin S, Santini GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol 1988;48:290-6.
20. 20. Serra HM, Krowka JF, Ledbetter JA, Pilarski LM. Loss of CD45R (Lp220) represents a post-thymic T cell differentiation event. J Immunol 1988;140: 1435-41.
21. 21. Kourtis AP, Ibegbu C, Nahmias AJ, Lee FK, Clark WS, Sawyer MK, et al. Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med 1997;335:1431-6.
22. 22. Gaulton GN, Scobie, JV, Rosenzweig M. HIV-1 and the thymus. AIDS 1997;11:403-14.
23. 23. Ibegbu CH, Spira TJ, Nesheim S, Mendez H, Lee F, Polliotti B, et al. Subpopulations of T and B cells in perinatally HIV-infected and noninfected age-matched children compared with those in adults. Clin Immunol Immunopathol 1994;71:27-32.
24. 24. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997;336:1337-42.
25. 25. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, for the UK Hemophilia Center Directors' Organisation. Importance of age at infection with HIV-1 for survival and development of AIDS in UK hemophilia population. Lancet 1996;347:1573-9.
26. 26. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
27. 27. Hammer SM, Kazenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
28. 28. Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med 1997;336:1704-12.
29. 29. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43:1-12.
30. 30. Denny T, Yogev R, Gelman R, Skuza C, Oleske J, Chadwick E, et al. Lymphocyte subsets in healthy children during the first 5 years of life. JAMA 1992;267:1484-8.
31. 31. Erkeller-Yuksel FM, Deneys V, Yuksel B, Hannet I, Hulstaert F, Hamilton C, et al. Age-related changes in human blood lymphocyte subpopulations. J Pediatr 1992;120:216-22.
32. 32. Mulder J, McKinney N, Christophersen C, Sninsky J. Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficieney virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
33. 33. Rousseeuw PJ, Leroy AM. Robust regression and outlier detection. New York: Wiley; 1987.
34. 34. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
35. 35. Bohler T, Nedel S, Debatin KM. CD95-induced apoptosis contributes to loss of primed/memory but no resting/naive T cells in children infected with human immunodeficiency virus type 1. Pediatr Res 1997;41:878-85.
36. 36. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St. Clair M, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS clinical trials group protocol 315. J Infect Dis 1998;178:70-9.
37. 37. Tough DF, Sprent J. Turnover of naive- and memory-phenotype T cells. J Exp Med 1994;179:1127-35.
38. 38. Young AJ, Hay JB, Mackay CR. Lymphocyte recirculation and life span in vivo. Curr Top Microbiol Immunol 1993;184:161-73.
39. 39. Mackall CL, Granger LA, Shepard MA, Cepeda R, Gress RE. T cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic derived versus thymic-independent progeny. Blood 1993;82:2585-94.
40. 40. Borkowsky W, Moore T, Krasinski K, Ajuang-Simbiri KO, Holzman R. Evolution of phenotypic memory T cells in HIV-1 infected infants and children. Clin Immunol Immunopathol 1992;63:280-4.
41. 41. Lukashov VV, Kuiken CL, Goudsmit J. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol 1995;69:6911-6.
42. 42. Bonhoeffer S, Coffin JM, Nowak MA. Human immunodeficiency virus drug therapy and virus load. J Virol 1997; 71:3275-8.
43. 43. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997;71:1089-96.
44. + memory T cells are the predominant population of HIV-1-infected lymphocytes in neonates and children. AIDS 1996;10:1477-84.
45. 45. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS. Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 1990:6058-62.
46. 46. Pinto L, Covas MJ, Victorino RMM. Loss of CD45RA and gain of CD45RO after in vitro activation of lymphocytes from HIV-infected patients. Immunology 1991;73:147-50.
47. 47. Janossy G, Borthwick N, Lomnitzer R, Medina E, Squire SB, Phillips AN, et al. Lymphocyte activation in HIV-1 infection. I. Predominant proliferative defects among CD45R0 cells of the CD4 and CD8 lineages. AIDS 1993; 7:613-5.